|
|
Post by uvula on Jan 28, 2017 13:21:21 GMT -5
Sorry, you are all wrong.
The big news on Wednesday is that there will be a MNKD Proboards dinner on Friday.
|
|
|
|
Post by deanbain on Jan 28, 2017 13:36:39 GMT -5
Maybe Afrezza re-launch 3.0?
|
|
|
|
Post by patten1962 on Jan 28, 2017 14:43:02 GMT -5
1/27/17, Nate thinks a partnership or buy-in will happen. I'd agree with him. Let's see how much cash infusion will be. Is it possible we will get a Quad crown corporate event on Tues 2/1/17: EpiHale IND, EpiHale partnership, Afrezza regional partners, Major Buy-in ? I have a feeling a real, sustainable short squeeze tsunami is finally forming this year if those events happen. Consider this a Tsunami Warning. Along with its efforts to develop inhalable ephinephrine (efforts that include what the company has called a “successful” meeting with the FDA back in December), the company is moving forward with projects to develop inhalable treprostinil and palonosetron, with an eye towards eventually partnering those products once they are further along in the clinic.And, speaking of “the clinic,” I believe it is also worth noting that Matt also pointed out at JPM that MannKind is moving forward with plans to conduct pediatric, dosing, and time-in-range clinical trials with Afrezza. In addition, once the commercial(s) have been approved by the FDA (expected in the April time-frame, if I remember correctly), MannKind is planning to rollout its first direct-to-consumer (DTC) TV ads (in very targeted markets at first, mind you). As you might imagine, these clinical trials and TV ads will all require time, personnel, and, money to bring them to fruition… and, once again, these are all things that it would appear on a first glance that MannKind does not have at its disposal, but, reading between the lines, may have “lined up” after all, even if a partnership and/or buy-in (or perhaps even a wildly unexpected – by outsiders – ramp in Afrezza scripts?) that would provide additional capital hasn’t actually been announced/revealed yet.Read more: mnkd.proboards.com/thread/7115/nates-notes-new-article-out#ixzz4X4sGViR9God I hope you're right. I really value your opinion and obviously Nates opinion. For the fun of it, let's say we get a deal with another company for epinephrine. Let's say we get 30 million, 60 million 120 million xcetera. What would be the corresponding stock prices in your opinion for such a deal? I know this is all speculation. I just really wonder what your thoughts are. If this is a crazy question and I get hammered, I'll delete the post. |
|
|
|
Post by lennymnkd on Jan 28, 2017 16:25:50 GMT -5
Can't see Dexcom not being part of the Tech equation/ / been my hope all along .. guess just have to Waite and see ... seems to be the what the future of diabetes is about ! And what better advantage for DEXCON than to "partner" with what AFFREZZA has to offer .
|
|
|
|
Post by babaoriley on Jan 28, 2017 18:18:35 GMT -5
Lakers, I applaud you, but you are swimming against a very strong current, let's hope you're salmon enough to do it!
|
|
|
|
Post by lakers on Jan 28, 2017 20:58:51 GMT -5
Lakers, I applaud you, but you are swimming against a very strong current, let's hope you're salmon enough to do it! You should add "and elusive enough not to be devoured by the hungry bears". This also applies to Mnkd. |
|
|
|
Post by mnkdfann on Jan 28, 2017 23:57:41 GMT -5
You know, based on the above (identical language used last year and this year), my expectations for the conference call are now 50/50 between one of (a) discussion of a RS and (b) the same old same old (nothing much). Interesting that this year they dropped 2016's "departing slightly from past practice for this call, stockholders who wish to submit questions in advance of the call". |
|
|
|
Post by sylvaing on Jan 29, 2017 7:29:50 GMT -5
I believe MNKD Management did plan for a RS over a year ago.....when DeSisto decide not to joined MNKD....it is because he was informed of the master plan and RS was into it... I do not believe that it was because on non competition agreement....since he could have joined once the agreemenent was expired...
|
|
|
|
Post by sportsrancho on Jan 29, 2017 9:19:26 GMT -5
I believe that MNKD was blindsided by SNY dumping us and, that's why DeSisto bailed. And that Matt never thought we would need a RS. And we may not. I think Matt thought that the run way that the SNY money gave us would push the stock up. JMO:-)
BTW, many people said SNY wouldn't give us a dime:-)
|
|
|
|
Post by mnholdem on Jan 29, 2017 9:33:22 GMT -5
Last February, MannKind conducted an investors conference a few weeks after their JPMorgan Conference presentation. The Feb 3 MannKind Investors Conference call began with these words: Matthew J. Pfeffer
Thank you, Rose. In addition to Rose, I’m also pleased to be here with MannKind’s Chief Medical Officer, Dr. Ray Urbanski. We plan to use today’s investor call to give a deeper update on several aspects of MannKind’s business than we had the time to go into at our recent JPMorgan Presentation.
For the first time, we’ll also be answering questions submitted from our retail investor community as well as answering live questions from covering analysts. As Ray and I provide updates on various topics today, we will answer many of the questions submitted related to that topic.
Read more: www.nasdaq.com/aspx/call-transcript.aspx?StoryId=3862956&Title=mannkind-s-mnkd-investor-conference-call-transcript-#ixzz4XA1UWeZO
I decided to post this historical information as a caution (especially for myself) to temper overly-optimistic expectations. This Investors Conference may have the identical purpose as the Feb-2016 conference: "to give a deeper update...than we had time to go into at our recent JPMorgan presentation". On Feb 3 MNKD was $0.99/share. One month later $1.10/share. It wasn't until after Matt's presentation at the 4Q15 (EOY) earnings call that MNKD rallied to $2.03/share. The February 2016 Investors Conference didn't result in much movement in share price at all. As I stated yesterday, I'm hoping for some new announcements but I'm expecting the call to consist largely of a "deeper" look for investors into management's plans for 2017.  |
|
|
|
Post by sylvaing on Jan 29, 2017 9:40:44 GMT -5
Hi SportsRancho,
For me what confirms that MNKD management knew that the SP would go below $1.00 and delisting will be an issue....is the fact that they went to get listing on the TASE exchange. It is oubious to me that they knew it and TASE is part of the plan of action..so consider a delisting from the NASDAQ
Cheers,
|
|
|
|
Post by saxcmann on Jan 29, 2017 10:42:42 GMT -5
Hi SportsRancho, For me what confirms that MNKD management knew that the SP would go below $1.00 and delisting will be an issue....is the fact that they went to get listing on the TASE exchange. It is oubious to me that they knew it and TASE is part of the plan of action..so consider a delisting from the NASDAQ Cheers, Sylvaing, I'm very confident you don't know what your talking about. You must be bored this morning? I think Sports has a good feel what's going on. I can assure you that you don't. I can confirm mnkd management did not know pps will go below $1 and delisting would be an issue. Ridiculous comments. |
|
|
|
Post by sportsrancho on Jan 29, 2017 10:44:54 GMT -5
Hi SportsRancho, For me what confirms that MNKD management knew that the SP would go below $1.00 and delisting will be an issue....is the fact that they went to get listing on the TASE exchange. It is oubious to me that they knew it and TASE is part of the plan of action..so consider a delisting from the NASDAQ Cheers, Is this what you are talking about? Going Dark: www.dorsey.com/newsresources/publications/2009/03/going-dark--voluntary-delisting-and-deregistrati__And why would this be better than a RS? And what does TASE have to do with it? |
|
|
|
Post by falconquest on Jan 29, 2017 11:00:19 GMT -5
I believe that MNKD was blindsided by SNY dumping us and, that's why DeSisto bailed. And that Matt never thought we would need a RS. And we may not. I think Matt thought that the run way that the SNY money gave us would push the stock up. JMO:-) BTW, many people said SNY wouldn't give us a dime:-) ....and right there is Matt's fatal flaw. He felt the good news of additional funds would "go a long way" toward moving the share price back to one dollar. Unfortunately Wall Street didn't agree. I keep beating this dead horse but you want the stock price to increase? Then sell more Afrezza, everything else is window dressing. Mannkind need to show they are a successful company, right now they are pure speculation. |
|
|
|
Post by therealisaching on Jan 29, 2017 11:18:12 GMT -5
Stock has moved + 55% since that call
|
|
